Submit news tips and press releases to Editor at WeeklyUniverse dot com. All submissions become property of the Weekly Universe and deemed for publication without compensation unless otherwise requested. Name and contact information only withheld upon request.


About Us





Conspiracy Watch

Consumer Watchdog

Girls In Black




Quirky & Bizarre


Weird Science


Hollywood Investigator

Horror Film Aesthetics

Horror Film Festivals

Horror Film Reviews

Tabloid Witch Awards




by Thomas M. Sipos, managing editor.  [April 24, 2004]





[]  A new miracle eyedrop -- non-patented and available over-the-counter without a prescription -- is dissolving cataracts!--- saving people from expensive and dangerous eye surgery -- and the FDA doesn't want YOU to know about it!

That's the shocking bombshell revelation of libertarian sci-fi writer J. Neil Schulman and his mother Betty, revealed in an exclusive interview with the Weekly Universe on April 20, 2004, in Culver City, California.

The Schulmans' discovery of this new miracle eyedrop was sparked by the tragic result of Betty Schulman's tragic first cataract surgery.

In 1997, Betty Schulman, now 79, was diagnosed with cataracts.  She was a poor candidate for cataract surgery, as she was already suffering from thrombocytosis, an elevated blood platelet count that may result in haemorrhaging or blood clots if left untreated. Betty had been prescribed hydroxyurea to "control" her platelet count.


* Tragic First Surgery


By September 1999, Betty's right eye had worsened to the point that cataract surgery was unavoidable. Prior to surgery, her haematologist assured Betty that her platelet count was currently normal, thanks to the hydroxyurea. 

But tragically, despite the assurances of modern medical science, Betty's eye surgery did not go well. During surgery, clotting developed in the blood vessels feeding the retina. The retina died within three to six minutes due to lack of oxygen.

The next day, Betty was blind in her right eye. "It was like a curtain coming down over my right eye," said Betty to the Weekly Universe.

Even more tragically, the cataract in her left eye continued to worsen. In December 2003, at an eye exam at UCLA's Jules Stein Eye Institute, Betty was told that if she didn't have cataract surgery in her remaining good eye, she'd go blind in four to five years. Frighteningly, she was given no guarantee that the same complication -- blood clotting and blindness -- would not reoccur. Her physician dare not overdose her on hydroxyurea to control her platelet count, because that could lead to fatal internal haemorrhaging.


* A Son's Outrage


J. Neil Schulman had accompanied his mother to that eye exam, and he refused to accept the physician's dire prognosis: eventual blindness through cataracts or possible blindness through surgery.  Neil demanded to know the physician's expertise, such as when he'd last done a survey of cataract cures, and the physician admitted that it had been four years.

"A lot can have happened in four years!" Neil retorted. The physician did not appreciate having his expertise questioned. "I'd really pissed him off," said Neil to the Weekly Universe. "He finally threw up his hands and said, okay, so do a search on Google. And that's just what I did!"


* The Miracle Eyedrop: N-Acetyl Carnosine


Arriving home, Neil googled "non-surgical treatment of cataracts". He discovered that -- for several years now! -- Europeans had been treating cataracts with a new miracle eyedrop -- developed in Russia by Mark Babizhayev -- that dissolves cataracts!

The key ingredient is N-Acetyl Carnosine -- a natural, non-controlled, non-patented enzyme.  Because it's a natural, non-controlled substance, it can be sold without a prescription, over the counter. Because it's non-patented, several companies are offering it in the US, keeping prices low due to free market competition.

However, because N-Acetyl Carnosine lacks FDA approval as a cataract cure, the companies selling it are wary of making claims for its being a cataract cure. The boxes containing the eyedrops only claim that the drops help "soothe tired eyes" -- and they list N-Acetyl Carnosine as an "inactive ingredient."

Does it work? Does N-Acetyl Carnosine dissolve cataracts?

Neil ordered N-Acetyl Carnosine drops (which is sold in the US under several brand names, such as Bright Eyes III and Can-C and Eye D'Clare), and Betty began using them in the last week of December, 2003. Within three months, she noticed an improvement in her left eye's vision.

"Before using the drops, my cataract had gotten so bad, I could not distinguish faces on TV, I could not read captions on TV, I had to use a magnifying glass to read my large-print Reader's Digest, and I had trouble walking without bumping into things" said Betty to the Weekly Universe. "But now, I can see where I'm going. I can even read normal-sized text with just my regular glasses -- no magnifying glass needed."

Even more amazingly, the eyedrops have no negative side effects. The only downside Betty noticed was that sometimes, for several hours after taking the eyedrops, her vision was blurry. This did not prevent the overall improvement of her vision.

"We believe that this momentary bluriness is the cataract sloughing off, much as one sloughs off a callous," Neil explained.

"Knowledge arrives unevenly," Neil added. "I realized that when I learned about Dr. Abraham Weber, who took an aspirin a day to prevent strokes in the 1930s.  He was ahead of establishment medical science by some fifty years. That's why I refused to believe the doctor who essentially told my mother she had no choice but to go blind. And that doctor was wrong. The eyedrops work!"


J. Neil Schulman's sf novels include the Prometheus Award- winning The Rainbow Cadenza, and most recently, Escape From Heaven.  The Weekly Universe previously covered Schulman's report on his mind-meld with God.
Read more about this astounding cataract miracle cure in: The Cataract Cure: The Russian Eye-Drop Breakthrough: The Story of N-acetylcarnosine.

Copyright 2004 by



Dr. Mark A. Babizhayev responds:

Your Information about N-acetylcarnosine eyedrops was incorrect. N-acetylcarnosine and its efficacious formulations have been patented by myself, worldwide. [Issued PCT Patent application: WO 2004/028536 A1]. My company, Innovative Vision Products (IVP), holds the worldwide patents for the use of N-Acetylcarnosine to address senile cataracts.

In addition to our 1993 European Union patent application, we have filed patent applications in the United States and additional countries around the globe.  [See these publications.] The only clinically efficacious Product on the market is Can-C TM available at and Its Private labels Ocuzyme and Bionational (Nu-Eyes) are also clinically effective to cure cataracts.

I wish to emphasize that there are serious potential risks to ocular health with long term application of any preparation used in the eye, and therefore usage should always be carefully considered and monitored by patients and their physicians. A very fragile and highly specific balance of purity for this formulation must be maintained to ensure safe and effective use of N-Acetylcarnosine eyedrops. Only formulae made to this specific purity and methodology, the patented formulae, have been proven in animal and human clinical trials to be efficacious, and most importantly, safe in long term use. Innovative Vision Products (IVP) is the patent holder and the only maker of the clinically proven N-Acetylcarnosine formula.

For public safety I established IVP to ensure that the highest quality of standards are maintained for formula production control. Unfortunately there are a few amoral companies, attempting to capitalize on this discovery, which are illicitly fabricating and touting inferior N-Acetylcarnosine for senile cataracts without the benefit of the specific purity level and methodology required to ensure efficacy and safety for eye use.

A number of these deceptive companies are actually referencing my research to promote their substandard product, thus damaging my reputation. Also, some are attempting to make their products more attractive by adding vitamins such as vitamin A and E. These vitamins, while by themselves may be beneficial to the eye, on the other hand have branched hydrocarbon skeletons that inhibit the activity of N-Acetylcarnosine, particularly in the critical cornea and conjunctiva of the eye.

More importantly, combinations of vitamins and N-Acetylcarnosine have not got any published clinical trials for either efficacy or safety. This could lead to damage of the eye surface with long term use, as was shown with L-Carnosine in our trials.

As the publisher of much research on this subject, I feel a responsibility to inform consumers of the fraudulent and dangerous products being promoted to the public. A simple way to determine if one is purchasing the safe, patented formula product is by the following statement, provided on the eyedrop labels by our approved distributors: N-Acetylcarnosine Patented by Innovative Vision Products. This phrase ensures that you have the exact formula and purity of eyedrop that was proven safe in our clinical trials.

For public safety, we shall vigorously defend our patents and issue injunctions against distributors of non-approved N-Acetylcarnosine anti-cataract eyedrops. We shall seek damages where appropriate. Sincerely, Mark Babizhayev MA, PhD, Email:

PS: All published works about this issue in the peer reviewed Journals are originated from this Group:

1. Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours J. Related Articles, Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R D. 2004;5(3):125-39. PMID: 15139774 [PubMed - in process]

2: Babizhayev MA, Nikolayev GM, Goryachev SN, Bours J, Martin R. Related Articles, Hydration properties of the molecular chaperone alpha-crystallin in the bovine lens. Biochemistry (Mosc).  2003 Oct;68(10):1145-55. PMID: 14616086 [PubMed - in process]

3: Babizhayev MA, Deyev AI, Yermakova VN, Davydova NG, Kurysheva NI, Doroshenko VS, Zhukotskii AV.  Related Articles, Image analysis and glare sensitivity in human age-related cataracts. Clin Exp Optom. 2003 May;86(3):157-72. PMID: 12767250 [PubMed - in process]

4: Babizhayev MA.  Related Articles, Links Glare disability and driving safety. Ophthalmic Res. 2003 Jan-Feb;35(1):19-25. PMID: 12566859 [PubMed - indexed for MEDLINE]

5: Babizhayev MA, Nikolayev GN, Goryachev SN, Bours J. Related Articles, NMR spin-echo studies of hydration properties of the molecular chaperone alpha-crystallin in the bovine lens.  Biochim Biophys Acta. 2002 Jul 29;1598(1-2):46-54.  PMID: 12147343 [PubMed - indexed for MEDLINE]

6: Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, Zhukotskii AV, Goldman IM.  Related Articles, Links Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D. 2002;3(2):87-103. PMID: 12001824 [PubMed - indexed for MEDLINE]

7: Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Kurysheva NI, Zhukotskii AV, Goldman IM. Related Articles, Links N-Acetylcarnosine, a natural histidine- containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides.  2001 Jun;22(6):979-94. PMID: 11390029 [PubMed - indexed for MEDLINE]

8: Babizhayev MA, Yermakova VN, Semiletov YA, Deyev AI. Related Articles, The natural histidine-containing dipeptide Nalpha-acetylcarnosine as an antioxidant for ophthalmic use.  Biochemistry (Mosc). 2000 May;65(5):588-98.  PMID: 10851037 [PubMed - indexed for MEDLINE]

9: Babizhayev MA, Semiletov YA, Lul'kin YA, Sakina NL, Savel'yeva EL, Deyev AI, Alimbarova LI, Barinskii IF, Nicolay J, Paillet C, Langrand G, Seguin F. Related Articles, Cellular signalling and free-radical modulating activities of the novel peptidomimetic L-glutamyl-histamine.Biochemistry (Mosc). 1999 May;64(5):510-22. PMID: 10381611 [PubMed - indexed for MEDLINE]

10: Babizhayev MA, Lozovskaya EL, Makareyeva EN, Lul'kin YA, Sapezhinskii II.  Related Articles, Photoprotector and antioxidant properties of histamine-containing peptidomimetics in the photooxidation of glycyltryptophan.Biochemistry (Mosc). 1998 May;63(5):523-8. PMID: 9632886 [PubMed - indexed for MEDLINE]

11: Babizhayev MA, Yermakova VN, Sakina NL, Evstigneeva RP, Rozhkova EA, Zheltukhina GA.  Related Articles, N alpha-acetylcarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant.Clin Chim Acta. 1996 Oct 15;254(1):1-21. Erratum in: Clin Chim Acta 1997 Mar 18;259(1-2):199-201. PMID: 8894306 [PubMed - indexed for MEDLINE]

12: Babizhayev MA. Related Articles, Failure to withstand oxidative stress induced by phospholipid hydroperoxides as a possible cause of the lens opacities in systemic diseases and ageing. Biochim Biophys Acta. 1996 Mar 1;1315(2):87-99. PMID: 8608175 [PubMed - indexed for MEDLINE]

13: Babizhayev MA, Bours J, Utikal KJ. Related Articles, Isoelectric focusing of crystallins in microsections of calf and adult bovine lens. Identification of water-insoluble crystallins complexing under nondenaturing conditions: demonstration of chaperone activity of alpha-crystallin.  Ophthalmic Res. 1996;28(6):365-74. PMID: 9032796 [PubMed - indexed for MEDLINE]

A reader, Parhatsathid, responds:

Actually Betty Schulman's cataract was caused by hydroxyurea supplements. Backing that off a bit would stop the cataract within 6 days. So while N Acetyl Carnosine might be helpful, in vitro tests showed that hydroxyurea was the cause and can reverse the cataract.

Tokai journal of experimental and clinical medicine, Vol.6, No.3(19810700) pp. 321-326, ISSN:03850005, Histopathology of Reversible Cataracts Produced by Hydroxyurea in vitro, MIKUNI Ikuo 1, 1Department of Ophthalmology, School of Medicine, Tokai University Hydroxyurea Epithel Cataract Rat A DNA synthesis inhibitor, hydroxyurea (HU) (5×10^M), was added to the organ culture medium for a rat crystalline lens (male, white Wistar rats weighing 100g).

1. On the 3rd day, a macroscopic examination revealed diffuse opacity of the posterior capsule.  Because of removal of HU from the culture medium on the 3rd day the crystalline lens had become lucid on the 6th day, approximately the same as that of the control of the 6th day. In a histopathological examination, the epithelial cells appeared to maintain a histo-architecture similar to that of the control. Lens fiber swelling was scarce at this time.

2. The crystalline lens cultured with HU showed diffuse opacity of the anterior capsule and localized opacity below the posterior capsule in a macroscopic examination on the 5th day. In histopathological examinations of the same culture, the lens epithelial cells and swelling of the lens fibers had disappeared.

[Posted October 21, 2007]


"Weekly Universe" and "" and "Mystic Gray Buddha" trademarks are currently unregistered, but pending registration upon need for protection against improper use. The idea of marketing these terms as a commodity is a protected idea under the Lanham Act. 15 U.S.C. s 1114(1) (1994) (defining a trademark infringement claim when the plaintiff has a registered mark); 15 U.S.C. s 1125(a) (1994) (defining an action for unfair competition in the context of trademark infringement when the plaintiff holds an unregistered mark). All articles copyright the author or